Addition of omega-3 fatty acid and coenzyme Q10 to statin therapy in patients with combined dyslipidemia
Abstract
BACKGROUND: Statins represent a group of drugs that are currently indicated in the primary and secondary prevention of cardiovascular events. Their administration can be associated with side effects and the insufficient reduction of triacylglyceride (TAG) levels. This study aimed to assess the effect of the triple combination of statins with omega-3 fatty acids and coenzyme Q10 (CoQ10) on parameters associated with atherogenesis and statin side effects. METHODS: In this pilot randomized double-blind trial, 105 subjects who met the criteria of combined dislipidemia and elevated TAG levels were randomly divided into three groups. In the control group, unaltered statin therapy was indicated. In the second and third groups, omega-3 PUFA 2.52 g/day (Zennix fa Pleuran) and omega-3 PUFA 2.52 g+CoQ10 200 mg/day (Pharma Nord ApS) were added, res//. At the end of the 3-month period (±1 week), all patients were evaluated. RESULTS: Significant reduction of hepatic enzymes activity, systolic blood preasure, inflammatory markers and TAG levels were detected in both groups in comparison to the control group. Activity of SOD and GPx increased significantly after additive therapy. Coenzyme Q10 addition significantly reduced most of the abovementioned parameters (systolic blood preasure, total cholesterol, LDL, hsCRP, IL-6, SOD) in comparison with the statin+omega-3 PUFA group. The intensity of statin adverse effects were significantly reduced in the group with the addition of CoQ10. CONCLUSIONS: The results of this pilot study suggest the possible beneficial effects of triple combination on the lipid and non-lipid parameters related to atherogenesis and side effects of statin treatment.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
A number of randomised controlled trials have reported that CoQ10 reduces statin-associated muscle symptoms, while others have failed to demonstrate a benefit.
“A number of these RCTs have reported that CoQ10 reduces SAMS [4-7], while other have failed to demonstrate a benefit [8-12].”
From Effect of Coenzyme Q10 on statin-associated myalgia and adherence to statin therapy: A systematic review and meta-analysis (2020) · cites this paper as [7]
Some studies included in previous meta-analyses were excluded from this review due to lack of a placebo control or due to treatment with another active substance.
“As a result, some studies included in previous meta-analyses were excluded due to the lack of a placebo control or due to the treatment with another active substance [4,7,10].”
From Effect of Coenzyme Q10 on statin-associated myalgia and adherence to statin therapy: A systematic review and meta-analysis (2020) · cites this paper as [7]
Risk of bias assessment shows an overall low risk of bias in four included studies and moderate to high risk in three studies.
“The risk of bias assessment shows an overall low risk of bias in four of the included studies with no considerable bias in all five underlying domains,(34,39,40,43) whereas the remaining three studies show an overall moderate to high risk of bias (Figure 2).(33,41,42)”
From Effects of coenzyme Q10 supplementation on myopathy in statin-treated patients: a systematic review and meta-analysis (2025) · cites this paper as [33]
Four out of seven included studies show a significant reduction of muscle pain intensity after CoQ10 supplementation compared to control, while three studies do not show a significant change.
“Four out of seven studies show a significant reduction of muscle pain intensity after CoQ10 supplementation compared to the control group,(33,39,40,42) while three studies do not show a significant change of muscle pain intensity(34,41,43) (Table 2).”
From Effects of coenzyme Q10 supplementation on myopathy in statin-treated patients: a systematic review and meta-analysis (2025) · cites this paper as [33]
Six out of seven studies administered CoQ10 in the intervention group and placebo in the control group; one trial compared CoQ10 plus n-3 fatty acids to n-3 fatty acids only.
“Six out of seven studies administer CoQ10 supplements in the intervention group and a placebo supplement in the control group.(34,39–43) One trial compares the supplementation of CoQ10 in combination with n-3-fatty acids (n-3 FA) in the intervention group to a control group taking n-3 FA only.(33)”
From Effects of coenzyme Q10 supplementation on myopathy in statin-treated patients: a systematic review and meta-analysis (2025) · cites this paper as [33]
Four studies stated SAMS as inclusion criterion, while three studies included patients with and without SAMS besides other side effects.
“Four studies stated SAMS as inclusion criterion,(34,41–43) while three studies included patients with and without SAMS besides other side effects.(33,39,40)”
From Effects of coenzyme Q10 supplementation on myopathy in statin-treated patients: a systematic review and meta-analysis (2025) · cites this paper as [33]
The citation lists haven’t been fetched yet
References 46 · Cited by 40
- Authors
- Tóth, Š., Šajty, M., Pekárová, T., Mughees, A., Štefanič, P., Katz, M., Spišáková, K., Pella, J., & Pella, D.
- Affiliations
- University of Pavol Jozef Šafárik (SK)
- Východoslovenský ústav srdcových a cievnych chorôb, a.s. (SK)
- St. Luke Highly Specialized Institute of Geriatrics , Košice , Slovakia
- Corresponding author
- Tóth, Štefan
- Venue
- Journal of Basic and Clinical Physiology and Pharmacology
- Publisher
- Walter de Gruyter GmbH
- Published
- 2017-05-23
- Volume
- 28
- Issue
- 4
- Pages
- 327-336
- ISSN
- 0792-6855 (ISSN-L)
- 2191-0286
- OpenAlex
- W2618221687
- Cited by
- 40
- References
- 46
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 1 · 2023: 7 · 2022: 8 · 2021: 2 · 2020: 4 · 2019: 6 · 2018: 3 · 2017: 4
- FWCI
- 3.87
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Basic and Clinical Physiology and Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Coenzyme Q10 studies and effects
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Keywords
- statins, omega-3 fatty acids, coenzyme Q10, hypertriglyceridemia, statin adverse effects, atherogenesis, oxidative stress, antioxidant enzymes, inflammatory markers, systolic blood pressure, lipid-lowering therapy
- MeSH terms
- Blood Pressure, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Lipids, Cholesterol, LDL, Male, Middle Aged, Pilot Projects, Triglycerides, Ubiquinone, Fatty Acids, Omega-3, Interleukin-6, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Dietary Supplements, Dyslipidemias
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
